Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
Anavex reported third fiscal quarter net income of $7.8 million, or $0.08 per share, compared to a net loss of $13.2 million in the prior year, driven primarily by the reversal of stock-based compensation expenses tied to the termination of the former CEO. The company ended the quarter with $118.3 million in cash, expected to fund operations into mid to late fiscal 2028, though it continues to work to regain compliance with Nasdaq after delaying its 10-Q filings.
Key figures
- Eps
- 0.08
- Net income
- 7800000
- Cash runway
- mid to late fiscal 2028
- Ga expenses
- -2000000
- Cash balance
- 118300000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.